Unlocking Rosacea Relief: Can Targeted Treatments Based on Tear Analysis Make a Difference?
"A new study explores how analyzing tear composition could personalize treatment for ocular rosacea, potentially leading to better outcomes."
Ocular rosacea is a chronic inflammatory condition affecting the eyes, often coexisting with skin rosacea. It leads to redness, dryness, irritation, and in severe cases, can threaten vision. Traditional treatments include warm compresses, lid hygiene, artificial tears, and, in some instances, antibiotics like azithromycin and doxycycline.
A recent study published in Karger Kompass Ophthalmologie investigates a novel approach to managing ocular rosacea: analyzing tear fluid to measure the levels of specific inflammatory markers, IL-1α and MMP-9. The goal is to see if these levels correlate with treatment response to azithromycin and doxycycline, potentially paving the way for more personalized and effective therapies.
The researchers aimed to identify whether pre-treatment tear fluid composition could predict how well patients would respond to either azithromycin or doxycycline, two commonly prescribed antibiotics. By understanding the role of IL-1α and MMP-9, doctors may be able to tailor treatments to individual patients, improving outcomes and reducing the burden of this chronic condition.
Prevalence and Clinical Burden
Ocular rosacea commonly presents with dry eye, foreign body sensation, and photophobia. A 2025 systematic review and meta-analysis reported that estimates of ocular rosacea among people with cutaneous rosacea range from 0.03% to 65%. Another review reported prevalence estimates ranging from 6% to 72% in rosacea populations, illustrating substantial variation between studies. Ocular manifestations remain poorly studied, and diagnosis may be delayed when skin symptoms are absent.
Conventional Treatment Gaps
Treatment options for ocular rosacea include eyelid hygiene, topical and oral antibiotics, cyclosporine ophthalmic emulsion, oral vitamin A derivatives, and intense pulsed light. Practical guidance generally describes a stepwise approach, beginning with local care and adapting treatment to ocular involvement. However, a 2024 systematic review noted that direct comparisons of treatment methods for ocular rosacea are lacking. Rosacea management more broadly has also moved toward phenotype-based classification and may involve monotherapy or multimodal treatment.
Tear Analysis: A New Frontier in Ocular Rosacea Treatment?
The study involved analyzing tear samples from patients with active ocular rosacea and a control group of healthy individuals. The researchers measured the levels of two key inflammatory markers: interleukin-1 alpha (IL-1α) and matrix metalloproteinase-9 (MMP-9). These markers are known to play a role in inflammation and tissue damage.
- Patient Enrollment: Participants with active ocular rosacea, meeting specific criteria from the National Rosacea Society, were recruited. A control group of healthy individuals was also included.
- Treatment Protocol: Patients were randomly assigned to receive either azithromycin (500 mg three times a week) or doxycycline (200 mg daily) for four weeks. All participants were also instructed to use warm compresses, lid massage, omega-3 supplements, and artificial tears.
- Tear Sample Collection: Tear fluid samples were collected from both eyes of all participants before and after the four-week treatment period.
- Cytokine Analysis: The levels of IL-1α and MMP-9 in the tear samples were measured using enzyme-linked immunosorbent assays (ELISA).
- Clinical Assessment: Symptoms were assessed using a questionnaire, and clinical improvement was defined as a 50% or greater reduction in symptoms.
Limits of Current Diagnosis and Therapy
Artificial tears and lubricating agents can relieve dry-eye symptoms associated with ocular rosacea, while systemic tetracyclines and macrolides are often used for moderate disease. These antibiotics may reduce inflammation, but reported adverse effects include gastrointestinal distress, photosensitivity, candidiasis, teratogenicity, Stevens-Johnson syndrome, and allergic reactions. Diagnosis is also challenging because no single test adequately establishes dry eye syndrome. The American Academy of Ophthalmology identifies clinical examination as the diagnostic gold standard.
Cyclosporine Versus Doxycycline
A comparative study evaluated topical cyclosporine A emulsion against oral doxycycline for rosacea-associated ocular changes and dry-eye complaints. The investigators screened 110 patients with rosacea, of whom 38 had the relevant ocular findings and symptoms described for the study. This design directly addressed two commonly used treatment approaches, although the source material does not provide the comparative outcome results. A clinical treatment guide likewise emphasizes that ocular rosacea can affect ocular health, appearance, and comfort and requires familiarity with multiple treatment options.
A Glimmer of Hope for Personalized Rosacea Care
This research offers a promising glimpse into the future of ocular rosacea treatment. By analyzing tear fluid for inflammatory markers like IL-1α and MMP-9, clinicians may be able to predict treatment response and tailor therapies to individual patients. While larger studies are needed, this approach could lead to more effective and personalized care, improving the lives of those affected by this chronic condition.
Toward Precision Treatment
Recent reviews describe ocular rosacea as a chronic inflammatory disorder affecting the ocular surface and associated with cutaneous rosacea. Reported mechanisms include genetic predisposition, immune dysfunction, neurovascular alterations, and microbiome dysregulation, which may contribute to epithelial barrier disruption. A 2025 trends analysis suggests that future rosacea research may integrate precision-medicine approaches by linking molecularly defined pathogenic mechanisms with standardized classification systems. These directions support continued investigation into more individualized treatment strategies.
Chronic Management and Diagnosis
The Mayo Clinic states that ocular rosacea is diagnosed through symptoms, medical history, and examination of the eyes, eyelids, and facial skin because there are no specific diagnostic tests or procedures. Medication and home eye care can usually control the condition, but they do not cure it, and ocular rosacea often remains chronic. Temporary oral antibiotics such as tetracycline, doxycycline, erythromycin, and minocycline may be prescribed, with longer treatment sometimes needed for severe disease. These requirements illustrate the ongoing management burden associated with the condition.
When Disease Becomes Refractory
A 2026 case report described resistant ocular rosacea that did not respond to topical steroid treatment and progressed to corneal perforation. The patient required numerous surgical interventions, and the condition was ultimately controlled with systemic steroids. A separate case report characterized ocular rosacea as frequently misdiagnosed and associated with prolonged inflammation and important visual consequences. Together, these reports show how severe or unrecognized disease can produce consequences beyond routine irritation and discomfort.